Metsera Calls Pfizer's Claims 'Nonsense' In Latest Buyout Battle Salvo

Metsera has rejected Pfizer's lawsuit as "nonsense," escalating the dispute over its acquisition after Novo Nordisk made an unsolicited $6.5 billion bid, surpassing Pfizer's prior $4.9 billion agreement. Pfizer is suing both companies, alleging Metsera breached its obligations and Novo is attempting to stifle competition in the weight-loss market, while Metsera contends Pfizer seeks a lower acquisition price. This battle highlights the strategic importance of Metsera's obesity drug pipeline for Novo, facing sales pressures on its key products, and for Pfizer, seeking to re-establish its presence in the lucrative weight-loss sector.

Analysis

Metsera (MTSR) has publicly rejected Pfizer's (PFE) lawsuit claims as "nonsense," escalating the dispute over its acquisition. This follows Novo Nordisk's (NVO) unsolicited $6.5 billion bid for Metsera, which significantly exceeded Pfizer's prior $4.9 billion agreement.

Pfizer alleges Metsera breached its original takeover obligations and that Novo aims to suppress competition in the lucrative weight-loss market. Metsera, however, contends Pfizer is attempting to litigate its way to a lower acquisition price, affirming its board's commitment to shareholder interests.

The acquisition battle highlights the strategic importance of Metsera's obesity drug pipeline for both pharma giants. Novo Nordisk seeks to bolster its position against potential sales declines for its semaglutide products (Wegovy/Ozempic) due to compounders and upcoming Medicare price negotiations, while Pfizer views Metsera as a critical opportunity to re-establish its presence in this high-growth therapeutic area after internal setbacks.

Market reaction saw Metsera stock decline 3.7% to $60.73, while Pfizer shares closed roughly flat at $24.66 and Novo Nordisk dipped less than 1% to $49.11. The ongoing litigation introduces significant uncertainty and potential regulatory hurdles, as Pfizer explicitly suggested any deal with Novo could face substantial antitrust scrutiny.

Key Decisions for Investors

• Closely monitor the legal proceedings between Pfizer and Metsera, as the outcome will significantly influence Metsera's acquisition trajectory and potential valuation.
• Assess the heightened regulatory and antitrust risks associated with a potential Novo Nordisk acquisition, which could introduce delays or complications.
• Evaluate the strategic implications for both Pfizer and Novo Nordisk in the lucrative obesity market, considering how the resolution of this dispute will shape their competitive positions.
• Consider the potential for increased volatility in MTSR shares due to the ongoing legal battle and competing bids, while observing the more muted impact on PFE and NVO.